On April 7th, British American Tobacco (BAT) announced a $10 million investment in a partnership with CBD company Charlotte's Web to develop a drug to treat neurological diseases. The investment is part of BAT's diversification plan for their business.
Establishment of a Joint Venture Company.
BAT subsidiary AJNA BioSciences PBC and Charlotte's Web have formed a joint venture and plan to seek approval from the US Food and Drug Administration (FDA) for a therapeutic drug made from cannabis extracts.
In this project, AJNA has invested $10 million. According to the agreement, Charlotte's Web and AJNA each own 40% of the entity, with the remaining shares belonging to BAT.
In the CBD industry, BAT has also invested in Canadian cannabis company OrganiGram and German cannabis company Sanity Group, and has joined Casa Verde Capital under Snoop Dogg's leadership.
Tobacco company's first attempt at entering pharmaceutical development
To date, few companies have taken action to apply for FDA authorization for CBD medications. Only one similar medication has received recognition, which is GW Pharma's Epidiolex, a seizure medication made from CBD. However, the FDA has indicated that it has also approved three synthetic marijuana-related medication products.
Jefferies analyst Owen Bennett stated in a research report that "this is the tobacco company's first attempt to enter the pharmaceutical development field. Given last year's sales of Epidiolex at $740 million, the outlook is quite attractive.
This joint venture is set to commence clinical research this year and describes the candidate drug as a "novel plant-based medication targeting neurological disorders". British American Tobacco has declined to reveal further details about the drug's treatment capabilities.
On Thursday, Charlotte's Web stock soared by as much as 21% while BAT's stock enjoyed a more modest increase of 1.5%.
Reference:
British American Tobacco has invested $10 million in a CBD brain drug.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
